Abbreviations & Acronyms B = bladder HR = hazard ratio K = kidney LRFS = local recurrence-free survival MFS = metastasis-free survival NR = not reported OS = overall survival P = paratesticular RMS = rhabdomyosarcoma Objectives: To report our institutional experience in the management of adult genitourinary sarcoma. Methods: This was a retrospective analysis of data on adult genitourinary sarcoma treated at the West China Hospital, Sichuan University, Chengdu, Sichuan, China from 1985 to 2010. Clinicopathological parameters were analyzed to determine their impact on overall, recurrence-free and metastasis-free survivals. Results: A total of 46 women and 142 men were included, with a median age of 42 years. Of these, 152 cases were high-grade. The most common site was the paratesticular region. Surgical resection was carried out in 155 patients (82.4%), with negative margin in 106. After a minimum follow up of 5 years, 20 patients (11.6%) survived disease-free, 14 (8.1%) were alive with disease and 138 (80.2%) died of disease. Survival rates at 1, 3 and 5 years were 91.3%, 64.0% and 47.7%. In univariate analyses, liposarcoma, high grade, metastasis at diagnosis, a lack of surgical resection and positive margin were predictive of unfavorable survival. In multivariate analyses, high grade, a lack of surgical resection and chemotherapy were independent predictors of poor survival. Conclusions: Adult genitourinary sarcoma is an aggressive malignancy, usually presenting at advanced stage, with a high incidence of recurrence and metastasis. Complete resection and selective combination of chemotherapy and radiotherapy might constitute the optimal treatment for this disease.
Introduction
Sarcomas of the genitourinary origin are exceedingly rare, and constitute approximately 2.1% of soft tissue sarcomas and 1-2% of malignant genitourinary tumors. 1, 2 Within the genitourinary tract, the most common histological subtypes are leiomyosarcoma, liposarcoma and rhabdomyosarcoma, which affected the paratesticular region, kidney, prostate, penis and bladder, in descending order. 3 Genitourinary sarcoma occurs even less commonly in adults, therefore, knowledge on clinical features, management, and survival of adult genitourinary sarcoma is primarily extrapolated from pediatric studies and counterparts of other anatomical sites. [4] [5] [6] [7] Currently, to our knowledge, the largest cohort included 131 cases from the Memorial SloanKettering Cancer Center, New York, New York, USA (published in 2006). 2 No recent large, institution-based publications are available. This has prompted the current report to further clarify the clinicopathological features, management and survival of 188 adult genitourinary sarcoma patients treated at the West China Hospital, Sichuan University, Chengdu, Sichuan, China between June 1985 and June 2010 (with a minimum follow up of 5 years or until patient death). We also carried out a PubMed search for adult genitourinary sarcoma, and provided a brief comparison of our cohort with others that have been published in the English literature. institution between June 1985 and June 2010. The present study only included sarcomas of the genitourinary tract, such as the paratesticular region, kidney, prostate, bladder, penis, seminal vesicle, ureter and urethra; the female genital tract, and retroperitoneal and pelvic sarcomas involving the genitourinary organs were excluded. Medical records of the target patients were thoroughly reviewed for clinical information regarding patient age at diagnosis, sex, clinical symptoms and past medical history. Tumor-associated factors, such as primary organ, tumor size, stage, histological subtype and grade were examined. Treatment-related characteristics including surgical modality, surgical margin status, and the application of chemotherapy and radiotherapy were also analyzed.
If the distinct histological subtype could not be determined, the sarcoma was considered as unclassified. Tumor grade was classified according to the French Federation of Cancer Center System Grading Scheme for Adult Sarcoma. Grade 1 sarcoma was classified as low grade, and grades 2 and 3 as high grade, as suggested by Deyrup et al. 8 Surgical margin was regarded as negative (complete resection), in the absence of microscopically and macroscopically residual tumor, from a consensus of both operation records and pathology reports. Follow-up data were collected at scheduled appointments in the outpatient department or by telephone interviews.
Statistical analysis
Primary end-points were time to death, recurrence and metastasis. OS time was measured from the date of diagnosis to the date of death or last follow up, LRFS from the date of operation to the date of recurrence and MFS from the date of diagnosis to the date of metastasis. Patients that survived or that did not develop recurrence or metastasis were censored at the last follow up. OS, LRFS and MFS rates were estimated using the Kaplan-Meier method, and differences in survival rates within patient subgroups were compared in univariate analysis using the log-rank test. The following patient subgroups were analyzed for prognostic value: age, sex, presenting symptoms at diagnosis, symptom duration, tumor size, tumor anatomic location, histological subtype, grade, metastasis at entry, surgical resection, margin status, the application of chemotherapy and radiotherapy. Multivariate analyses of potential factors with expected clinical value (regardless of the statistical significance shown after univariate analyses) were carried out through the Cox proportional hazards model. All statistical analyses were carried out by SAS 9.0 software (SAS Institute, Cary, NC, USA), with P < 0.05 to be statistically significant.
Results

Characteristics of adult patients with genitourinary sarcoma
A total of 188 adult cases of primary genitourinary sarcoma were treated at our institution between June 1985 and June 2010. Among them, 41 cases of adult renal sarcoma and 25 cases of prostate sarcoma have been published previously; 9, 10 nevertheless, in the present study, we enrolled more cases and extended the follow-up duration for a minimum of 5 years or until patient death. Clinicopathological characteristics of the 188 cases are summarized in Table 1 . Of 188 patients, 68 (36.2%) were smokers, and three (1.6%) had previous radiation exposure to the tumor location. The distribution of tumor location was as follows: paratesticular (n = 56, 29.8%), followed by kidney (n = 49, 26.1%), bladder (n = 40, 21.3%), prostate (n = 30, 16.0%) and other sites (n = 13, 6.9%). The most common histological subtype was leiomyosarcoma (n = 77, 41.0%), followed by liposarcoma (n = 38, 20.2%) and rhabdomyosarcoma (n = 36, 19.1%). A total of 14.1% of patients without metastasis at presentation did not undergo surgical resection, the main reason for which was poor general or economic conditions. Neoadjuvant, adjuvant or palliative chemotherapy and radiotherapy were not consistently administered during the 25-year period, and detailed information was limited. In brief, the chemotherapy regimen primarily consisted of paclitaxel-, cisplatin-, pirarubicin-, ifosfamide-, dacarbazine-and vincristine-based protocols, and radiotherapy was applied at a fractionated dose.
Overall survival
Among the 188 adult genitourinary sarcoma cases, 16 patients were lost to follow-up after initial completion of treatment and were excluded from the survival analyses. Thus, the survival analyses were restricted to the remaining 172 cases. At the end of June 2015, 20 patients (11.6%) survived disease-free, 14 (8.1%) were alive with disease and 138 (80.2%) died of disease. OS at 1, 3 and 5 years was 91.3%, 64.0% and 47.7%, respectively, and estimated median OS was 55 months. Median survival of those dying of disease was 41 months (range 3-155 months). The KaplanMeier curve of OS stratified by the primary organ is shown in Figure 1 , and univariate/multivariate analyses of potential prognostic factors on OS is shown in Table 2 . In univariate analyses, liposarcoma, high histological grade, metastatic disease at diagnosis, a lack of surgical resection, positive surgical margin and the application of radiotherapy were predictive of unfavorable OS. Multivariate analyses showed that patient age ≤50 years, high histological grade, a lack of surgical resection and chemotherapy were the independent prognostic predictors of poor OS.
LRFS
Analysis of LRFS was confined to the 116 patients in the surgical group: 102 with negative surgical margin and 14 with microscopically residual tumor. At last follow up, 75 patients (64.7%) developed local recurrence, and estimated median time to recurrence was 25 months. The margin status of 75 patients who underwent surgical resection and developed local recurrence was negative in 61 patients and positive in 14, whereas the margin status of 41 patients who underwent surgical resection and did not develop local recurrence was negative. The LRFS rate at 1, 3 and 5 years was 76.7%, 41.4% and 34.6%, respectively. Median survival after recurrence was 42 months (range 4-144 months). In univariate analyses, kidney origin (HR 1.92, 95% CI 1.05-3.50, P = 0.03), female sex (HR 1.68, 95% CI 1.01-2.81, P = 0.04), metastasis at entry (HR 9.17, 95% CI 1.19-71.4, P = 0.03) and positive surgical margin (HR 5.29, 95% CI 2.87-9.80, P < 0.01) were the significant predictors of unfavorable LRFS. On the contrary, patient age, presenting symptoms at admission, symptom duration, tumor size, histological subtype, histological grade, chemotherapy and radiotherapy had no significant influence on LRFS. In multivariate analyses, female sex (HR 1.81, 95% CI 1.01-3.24, P = 0.04), age ≤50 years (HR 1.86, 95% CI 1.11-3.12, P = 0.02) and positive surgical margin (HR 7.30, 95% CI 3.62-14.7, P < 0.01) were independent prognostic predictors of unfavorable LRFS (more details are shown in Table S1 ).
Metastasis-free survival
Analysis of MFS was confined to the 135 patients presenting without metastasis at entry. At last follow up, 88 patients (65.2%) developed metastasis, and the estimated median time to metastasis was 40 months. The MFS rate at 1, 3 and 5 years was 88.1%, 56.5% and 34.9%, respectively. Median survival after metastasis was 21 months (range 0-60 months). In univariate analyses, a lack of surgical resection (HR 13.72, 95% CI 4.86-38.73, P < 0.01), positive surgical margin (HR 2.16, 95% CI 1.31-3.56, P < 0.01) and the application of radiotherapy (HR 2.00, 95% CI 1.30-3.07, P < 0.01) were the significant predictors of unfavorable MFS. On the contrary, primary organ, sex, patient age, presenting symptoms at admission, symptom duration, tumor size, histological subtype, grade and chemotherapy had no significant influence on MFS. In multivariate analyses, positive surgical margin (HR 8.85, 95% CI 2.92-27.0, P < 0.01), a lack of chemotherapy (HR 1.75, 95% CI 1.05-2.92, P = 0.03) and the application of radiotherapy (HR 1.80, 95% CI 1.09-2.97, P = 0.02) were independent prognostic predictors of poor MFS (more details are shown in Table S2 ).
Discussion
Because of the rarity, even in large institutions it is difficult to accumulate sufficient cases to delineate the clinicopathological characteristics of adult genitourinary sarcoma, and draw conclusions on predictors of OS, RFS and MFS. Table 3 summarizes six clinical series on adult genitourinary sarcoma and provides comparisons with the present study. 2, 3, [11] [12] [13] [14] To the best of our knowledge, our series (188 adult cases over a 25-year period) represents the largest cohort of adult genitourinary sarcoma worldwide. The median age at diagnosis in our patients was 42 years, much younger than previous series (range 47.1-61 years). Men made up 76% of our patients, the predominant location was the paratesticular region and the most common histological subtype was leiomyosarcoma, which corresponded to the findings of other investigators. 2, 11 The 5-year survival rate in our series was among the lowest in published studies. This is most probably attributed to a larger tumor size (median 8 cm), a higher proportion of metastatic disease (25.5%), a higher percentage of high-grade tumors (80.9%), a higher frequency of leiomyosarcoma (41%) and a lower proportion of surgical resection (82.4%).
Surgical treatment can be broadly divided into those in which resection of the tumor is part of multimodal therapy with curative intent and those that palliate symptoms. The present study found that surgical resection was the most important prognostic indicator of long-term survival. Patients amenable to complete resection experienced longer median survival compared with incompletely resected or unresected disease (70 vs 49, 10 months), which is similar to a series from the Memorial Sloan-Kettering Cancer Center reporting survival of 8.9 years with complete resection and 1.5 years with only partial tumor resection or only biopsy, respectively. 2 On the basis of these findings, all patients with potentially resectable genitourinary sarcoma should undergo surgical exploration. Some patients without metastasis at 8 (40) 3 (15) 18 (90) 16 ( 102 (78) 29 (21) >107 ( presentation did not undergo resection, for which the main reason was very poor general condition. However, the ability to achieve complete resection remains a challenge. 15 This difficulty, related to the paucity of specific symptoms contributing to a late presentation and a far-advanced stage, 16 and the propensity of genitourinary sarcoma to invade critical abdominal and pelvic structures, 17 is evident in the finding of positive margins in 20.9% of our patients. In our daily clinical practice, we tended to carry out salvage chemotherapy and/or radiotherapy for patients with positive surgical margins; just three patients with positive surgical margins underwent reoperation of residual tumor resection. In the context of palliation, surgery can relieve symptoms (severe hematuria, urinary or bowel obstruction) to improve quality of life, such as palliative urinary and/or stool diversion. 10, 18 It is clear that all members of genitourinary sarcoma share the propensity for recurrence and metastasis. 19 A total of 65% of our patients developed local recurrence and the estimated median time to recurrence was 25 months, whereas 65% developed metastasis and the estimated median time to metastasis was 40 months. The explanations for the relatively high rate of recurrence and metastasis are multiple, and include patient reluctance of consultation, failure of early diagnosis and limited access to medical care, particularly in the developing countries. 20 Six patients with isolated recurrence and three with isolated metastasis in the present series were successfully salvaged by resection with or without chemotherapy or radiotherapy and had a median survival of 50 months. Dotan et al. reported that initial tumor size was the only factor predictive of RFS, and patient age, tumor grade and tumor histology were predictive of MFS.
2 However, we found that kidney origin, female sex, metastasis at entry and positive surgical margin were the significant predictors of unfavorable RFS, and a lack of surgical resection and positive surgical margin were the significant predictors of unfavorable MFS. Interpretation of different results between two studies is explained by the fact that analyses was uncontrolled and retrospective, and Dotan did not analyze the impact of multimodal neoadjuvant or adjuvant chemotherapy and/or radiotherapy in addition to surgical resection. 2 Advances in multidisciplinary management over the past decades have significantly increased the OS of adult sarcoma. 12, 21 In the present study, the 43 patients managed with a combination of surgical resection plus radiotherapy plus chemotherapy had a mean survival of 55 months versus 76 months for the 67 patients treated with surgery plus chemotherapy, 39 months for the eight patients treated with surgery plus radiotherapy, 69 months for the 29 patients treated with surgery alone and 13 months for the 25 patients treated without surgery. The application of radiotherapy being associated with an unfavorable outcome might have resulted from a selection bias. In our experience, patients with a high histological grade, tumor size >10 cm, incomplete resection or metastatic disease had a rather poor outcome, and should be considered as candidates for neoadjuvant and/or adjuvant treatment protocols. The present series is the first study to find that adult genitourinary sarcoma showed a favorable response to chemotherapy. Furthermore, molecular biomarkers continue to shed light onto the pathogenesis of sarcoma, and are increasingly being incorporated into risk stratification, identifying new targets for therapy. 22, 23 Interdisciplinary research efforts are warranted to evaluate these diagnostic and therapeutic innovations in patients with enrollment in clinical trials whenever possible.
The present study, despite being large, was not free of some limitations, including: (i) the rarity of sarcoma might cause potential bias regarding clinical characteristics and survival analysis imposed by the different number of patients in each subgroup, leading to potentially limited generalizability; (ii) it is retrospective in nature, and so some data are missing or unavailable; (iii) the lack of concurrent control group; and (iv) heterogeneity in the skill levels, and experience of the surgeons, together with the lack of neoadjuvant and adjuvant treatments for metastatic disease were not included in analysis.
In conclusion, adult genitourinary sarcoma is a group of exceedingly rare, but aggressive, neoplasms that often affects younger adults, with a poor prognosis, significant mortality owing to late diagnosis, advanced stage at presentation and rapid clinical progression. Surgical resection, when feasible, and selective combination of chemotherapy and radiotherapy play the leading role in its management, and should be attempted in all potential patients.
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Editorial Comment
Editorial Comment from Dr Ito to Adult genitourinary sarcoma: Clinical characteristics and survival in a series of patients treated at a high-volume institution Genitourinary soft-tissue sarcoma (GU-STS) is a rare disease, and the standard treatment has not been established because of the difficulty in the accumulation of the number of cases. The current study by Wang et al. is the largest cohort study evaluating 188 patients with GU-STS. 1 The importance of surgical resection was reconfirmed, and the authors showed an efficacy of chemotherapy combined with surgery. The limitation of their study was that they could not show the details of chemotherapy protocols for various sarcomas. However, it is of note that they first showed a possibility of chemotherapy to improve patients' prognosis in GU-STS.
In their study, surgical resection had a strong impact on patients' survival, and patients who have unresectable disease showed a very poor prognosis. Another study evaluating a large number of GU-STS patients also reported that complete surgical resection possibly achieved prolonged disease-specific survival. 2 Also, surgical resection with a negative surgical margin was quite important for decreasing the local recurrence rate in the current study. All patients who did not have a local relapse could be resected with a negative surgical margin. Furthermore, surgical margin status was an independent predictor for metastasis. However, a definition of a safe surgical margin is still unclear in GU-STS. The safety margin was reportedly >2-cm wide in bone and soft tissue sarcoma. 3 The concept of a curative surgical margin should be established for GU-STS.
The necessity of surgical resection of locally recurrent disease needs to be clarified. In the current series, the median time to local recurrence was 25 months, and the median time to metastasis was 40 months. These results might suggest that local relapse is likely to occur first, and metastasis occurs after local relapse in many cases. If surgical resection of the recurrent lesion is possible, it would be better to carry out surgery to delay metastatic presentation.
One point especially worth mentioning is that they showed the efficacy of chemotherapy for GU-STS. It was a pity that they did not show the details of the chemotherapy protocols. Effective chemotherapy after surgery should be determined for each sarcoma type. Also, GU-STS patients for whom adjuvant chemotherapy can be omitted need to be determined. In recent years, the efficacy of one of the tyrosine kinase inhibitors, pazopanib, for STS has been shown. 4 Because the response to pazopanib was variable for sarcoma types, tumor histology should be taken into consideration with pazopanib use. Also, efficacies of new chemotherapeutic agents including eriblin and trabectedin have been shown in STS treatment. 5 Although the appropriate choice of drug is difficult at the present time, the combination of surgical resection and adjuvant chemotherapy appears to be a mainstream GU-STS treatment.
In the current study, patients undergoing radiation therapy had a poor prognosis. However, the patient population that received radiation therapy might be biased, because these patients with a poor prognosis included patients whose tumors were unresectable. The efficacy of radiation therapy combined with surgery and chemotherapy was
